GIS:ETR
Gilead Sciences
134,50 €
arrow_upward
+0,64%(+0,86) 1K
12-okt, 17:35:57 (GMT+2) · EUR
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoGIS tikeri uchun statistika yaratilmoqda...
Ochish
134,84 €
Yuqori
135,84 €
Past
134,34 €
Bozor kapitali
186,53Â mlrd
Oʻrtacha hajm
683,00
Hajmi
1,08Â ming
52 haftalik eng yuqori
136,24 €
52 haftalik eng past
98,96 €
Xodimlar soni
17Â ming
Ochish
134,84 €
Yuqori
135,84 €
Past
134,34 €
Bozor kapitali
186,53Â mlrd
Oʻrtacha hajm
683,00
Hajmi
1,08Â ming
52 haftalik eng yuqori
136,24 €
52 haftalik eng past
98,96 €
Xodimlar soni
17Â ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Yahoo Finance
·
9 soat oldin
Gilead Sciences' Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says
Insider Monkey
·
10 soat oldin
Can Gilead (GILD) Stock Continue Rising in 2027?
Investing.com
·
12 soat oldin
BofA raises Gilead Sciences stock price target on growth outlook
ad-hoc-news.de
·
13 soat oldin
RBC raised target for Gilead Sciences stock to USD 126.00
Profil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Gilead Sciences haqida
CEODaniel O'Day
Xodimlar soni17Â ming
Asos solingan22-iyn, 1987
Bosh ofislarFoster City, Kaliforniya, Amerika Qo‘shma Shtatlari
Sektor-
Veb-saytgilead.com